Prioritizing health system and disease burden factors: an evaluation of the net benefit of transferring health technology interventions to different districts in Zimbabwe

References

• ArasaratnamAHumphreysGEmerging economies drive frugal innovationBull World Health Organ20139116723397344
   PubMed Web of Science ®Google Scholar
• OsikaJAltmanDEkbladhLKatzINguyenHRosenfeldJWilliamsonTTaperaSZimbabwe health system assessmentBethesda, MDHealth Systems 20/20 Project, Abt Associates Inc2010
   Google Scholar
• DrummondMMancaASculpherMIncreasing the generalizability of economic valuations: recommendations for the design, analysis, and reporting of studiesInt J Technol Assess Health Care200521216517115921055
   PubMed Web of Science ®Google Scholar
• CambonLMinaryLRiddeVAllaFTransferability of interventions in health education: a reviewBMC Public Health20121249722747988
   PubMed Web of Science ®Google Scholar
• MancaAWillanAR‘Lost in translation’: accounting for between country differences in the analysis of multinational cost effectiveness dataPharmacoeconomics200624111101111917067195
   PubMed Web of Science ®Google Scholar
• Guidelines for the Economic Evaluation of Health technologies in Ireland [webpage on the Internet]Health Information and Quality Authority2010 Available from: https://www.hiqa.ie/publication/guidelines-economic-evaluation-health-technologies-irelandAccessed September 1, 2016
   Google Scholar
• GoereeRBurkeNO’ReillyDMancaABlackhouseGTarrideJETransferability of economic evaluations: approaches and factors to consider when using results from one geographic area for anotherCurr Med Res Opin200723467168217407623
   PubMed Web of Science ®Google Scholar
• herald.co.zw [homepage on the Internet]Ministry defends procurement of Para-Check malaria tests kitsThe Herald2012 [cited November 4, 2012]. Available from: http://www.herald.co.zw/ministry-defends-procurement-of-para-check-malaria-test-kits/Accessed September 1, 2016
   Google Scholar
• MboeraLEFanelloCIMalimaRCTalbertAFogliatiPBobbioFMolteniFComparison of the Paracheck-Pf test with microscopy for the confirmation of Plasmodium falciparum malaria in TanzaniaAnn Trop Med Parasitol2006100211512216492359
   PubMed Web of Science ®Google Scholar
• KamugishaMLMsangeniHBealeEMalecelaEKAkidaJIshengomaDRLemngeMMParacheck Pf compared with microscopy for diagnosis of Plasmodium falciparum malaria among children in Tanga City north-eastern TanzaniaTanzan J Health Res2008101141918680960
   PubMedGoogle Scholar
• McNerneyRCunninghamJHepplePZumlaANew tuberculosis diagnostics and rolloutInt J Infect Dis201532818625809761
   PubMed Web of Science ®Google Scholar
• AbdurrahmanSTEmenyonuNObasanyeOJThe hidden costs of installing Xpert machines in a tuberculosis high-burden country: experiences from NigeriaPan Afr Med J20141827725489371
   PubMedGoogle Scholar
• KrizaCHanass-HancocckJOdameEAA systematic review of health technology assessment tools in sub-Saharan Africa: methodological issues and implicationsHealth Res Policy Syst2014126625466570
   PubMed Web of Science ®Google Scholar
• GavazaPRascatiKBrownCLawsonKMannTThe state of health economic and pharmacoeconomic evaluation research in Zimbabwe: a reviewCurr Ther Res Clin Exp200869326828524692805
   PubMed Web of Science ®Google Scholar
• TambourMZethraeusNJohannessonMA note on confidence intervals in cost-effectiveness analysisInt J Technol Assess Health Care19981434674719780533
   PubMed Web of Science ®Google Scholar
• StinnettAAMullahyJNet health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysisMed Decis Making1998182 SupplS68S809566468
   PubMed Web of Science ®Google Scholar
• BriggsAHGoereeRBlackhouseGO’BrienBJProbabilistic analysis of cost effectiveness models: choosing between treatment strategies for gastroesophageal reflux diseaseMed Decis Making200222429030812150595
   PubMed Web of Science ®Google Scholar
• HochJSDewaCSAdvantages of the net benefit regression framework for economic evaluation of interventions in the workplace. a case study of the cost-effectiveness of a collaborative mental health care program for people receiving short-term disability benefits for psychiatric disordersJ Occup Environ Med201456444144524662952
   PubMed Web of Science ®Google Scholar
• BoulengerSNixonJDrummondMUlmannPRiceSde PouvourvilleGCan economic evaluations be made more transferable?Eur J Health Econ20056433434616249933
   PubMedGoogle Scholar
• HansenKSChapmanGSetting priorities for the health care sector in Zimbabwe using cost effectiveness analysis and estimates of disease burdenCost Eff Resour Alloc200861418662389
   PubMedGoogle Scholar
• ShamuSRusakanikoSHongoroCA characterisation and profiling of District health indicators in Zimbabwe. An application of Principal Component Analysis in a data limited settingJournal of Health Economics and Outcomes Research201532162179
   Google Scholar
• BatwalaVMagnussenPHansenKNuwahaFCost-effectiveness of malaria microscopy and rapid diagnostic tests versus presumptive diagnosis: implications for malaria control in UgandaMal J201110372
   Web of Science ®Google Scholar
• KoenigSPBangHSeverePCost-effectiveness of early versus standard antiretroviral therapy in HIV-infected adults in HaitiPLoS Med201189e100109521949643
   PubMed Web of Science ®Google Scholar
• GrieveRNixonRThompsonSGCairnsJMultilevel models for estimating incremental net benefits in multinational studiesHealth Econ200716881582617191271
   PubMed Web of Science ®Google Scholar
• MarseilleELarsonBKaziDSKahnJGRosenSThresholds for the cost effectiveness of interventions: alternative approachesBull World Health Organ201593211812425883405
   PubMed Web of Science ®Google Scholar
• MugfordMHuttonGFox-RushbyJMethods for economic evaluation alongside a multicentre trial in developing countries: a case study from the WHO Antenatal Care Randomised Controlled TrialPaediatr Perinat Epidemiol199812Suppl 275979805724
   PubMed Web of Science ®Google Scholar
• StalhammarNOCarlsonJPeacockRCost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux diseasePharmacoeconomics1999165 Pt 148349710662395
   PubMed Web of Science ®Google Scholar
• LeeseBHuttonJMaynardAA Comparison of the costs and benefits of recombinant human erythropoietin (epoetin) in the treatment of chronic renal failure in 5 European countriesPharmacoeconomics19921534635610146999
   PubMedGoogle Scholar
• SculpherMJPangFSMancaAGeneralisability in economic evaluation studies in healthcare: a review and case studiesHealth Technol Assess2004849iiiiv1192
   Web of Science ®Google Scholar
• HountonSNewlandsDApplying the net-benefit framework for analysing and presenting cost effectiveness analysis of a maternal and newborn health interventionPlos One201277e4099522829906
   PubMed Web of Science ®Google Scholar